Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Stavudine, Lamivudine, Nevirapine Drug Combination

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 811471-91-7, 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione, Lamivudine; stavudine; nevirapine, Lamivudine/nevirapine/stavudine, Stavudine, lamivudine and nevirapine, Lamivudine mixture with nevirapine and stavudine
    Molecular Formula
    C33H37N9O8S
    Molecular Weight
    719.8  g/mol
    InChI Key
    FEOBXHIFUYOHBP-KPTOQMEFSA-N
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
    2.1.2 InChI
    InChI=1S/C15H14N4O.C10H12N2O4.C8H11N3O3S/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10;1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8;9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h2-3,6-8,10H,4-5H2,1H3,(H,18,20);2-4,7-8,13H,5H2,1H3,(H,11,14,15);1-2,6-7,12H,3-4H2,(H2,9,10,13)/t;7-,8+;6-,7+/m.00/s1
    2.1.3 InChI Key
    FEOBXHIFUYOHBP-KPTOQMEFSA-N
    2.1.4 Canonical SMILES
    CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4.CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO.C1C(OC(S1)CO)N2C=CC(=NC2=O)N
    2.1.5 Isomeric SMILES
    CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4.CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO.C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Stavudine - Lamivudine - Nevirapine

    2. Stavudine, Lamivudine, Nevirapine Drug Combination

    3. Triomune

    2.2.2 Depositor-Supplied Synonyms

    1. 811471-91-7

    2. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one;1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione

    3. Lamivudine; Stavudine; Nevirapine

    4. Lamivudine/nevirapine/stavudine

    5. Stavudine, Lamivudine And Nevirapine

    6. Lamivudine Mixture With Nevirapine And Stavudine

    7. Stv & Lmv & Nvp

    8. Lamivudine, Nevirapine, And Stavudine Fixed-dose Tablet

    9. Nevirapine & Lamivudine & Stavudine

    10. 11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & (-)-(2'r,5's)-1-[2'-hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine & Thymidine, 2',3'-didehydro-, 3'-deoxy-

    11. 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 11-cyclopropyl-4-methyl-5h-dipyrido[[?],[?]][1,4]diazepin-6-one; 1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione

    2.3 Create Date
    2007-03-19
    3 Chemical and Physical Properties
    Molecular Weight 719.8 g/mol
    Molecular Formula C33H37N9O8S
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count5
    Exact Mass719.24858035 g/mol
    Monoisotopic Mass719.24858035 g/mol
    Topological Polar Surface Area250 Ų
    Heavy Atom Count51
    Formal Charge0
    Complexity1120
    Isotope Atom Count0
    Defined Atom Stereocenter Count4
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count3
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameLamivudine; stavudine; nevirapine
    Active Ingredientstavudine; Lamivudine; nevirapine
    Dosage FormTablet; Tablet, dispersible
    Routeoral
    Strength100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg
    Market StatusTentative Approval
    CompanyCipla

    2 of 2  
    Drug NameLamivudine; stavudine; nevirapine
    Active Ingredientstavudine; Lamivudine; nevirapine
    Dosage FormTablet; Tablet, dispersible
    Routeoral
    Strength100mg; 6mg; 30mg; 200mg; 150mg; 12mg; 50mg; 30mg; 40mg; 60mg
    Market StatusTentative Approval
    CompanyCipla

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Anti-HIV Agents

    Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)

    Reverse Transcriptase Inhibitors

    Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)

    5.2 ATC Code

    J - Antiinfectives for systemic use

    J05 - Antivirals for systemic use

    J05A - Direct acting antivirals

    J05AR - Antivirals for treatment of hiv infections, combinations

    J05AR07 - Stavudine, lamivudine and nevirapine